SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001590750-22-000007
Filing Date
2022-05-13
Accepted
2022-05-13 07:23:14
Documents
57
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mgen-20220331.htm   iXBRL 10-Q 1089679
2 EX-3.2 vrdn_amendedandrestatedbyl.htm EX-3.2 94236
3 EX-31.1 ex311_2022-03.htm EX-31.1 11316
4 EX-31.2 ex312_2022-03.htm EX-31.2 13078
5 EX-32.1 ex321_2022-03.htm EX-32.1 9889
  Complete submission text file 0001590750-22-000007.txt   5776023

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mgen-20220331.xsd EX-101.SCH 37397
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mgen-20220331_cal.xml EX-101.CAL 42067
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mgen-20220331_def.xml EX-101.DEF 228753
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mgen-20220331_lab.xml EX-101.LAB 530781
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mgen-20220331_pre.xml EX-101.PRE 332987
51 EXTRACTED XBRL INSTANCE DOCUMENT mgen-20220331_htm.xml XML 898110
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36483 | Film No.: 22920227
SIC: 8071 Services-Medical Laboratories